Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Read More
New data presented at ATS 2024 show the potential of Tezspire to play a role in the future treatment of COPD.
Read More
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read More
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
Read More
Tezspire (tezepelumab) demonstrated reductions in the annualized asthma exacerbation rate across biomarker subgroups of patients with severe asthma.
Read More
The FDA approved AstraZeneca and Amgen’s medication, Tezspire, to treat severe asthma for patients aged 12 years and older.
Read More
A Phase 3 trial of AstraZeneca/Amgen’s Tezepelumab found the drug had a clinically meaningful 77% reduction in annualized asthma exacerbation rates in patients with severe asthma.
Read More
